Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro - Top-Institutions - MDSpire

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • By

  • Yi-Ping Shih

  • Stephan Drokin

  • Olivia Burke

  • Huayu Huang

  • Amy Leung

  • Marco Bravo-Manriquez

  • Myungkyu Jang

  • Marina S. Syrkina

  • Laura Julian

  • Nelson Sanjuan

  • Eric Tran

  • May 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Cell Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Cell Therapy

  • #3

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology
    • Cell Therapy

  • #4

    Baylor College of Medicine
    Baylor College of Medicine

    Houston, Texas

    Key Differentiators

    • Oncology
    • Cell Therapy

  • #5

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Cell Therapy

Original Source(s)

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • by Yi-Ping Shih, Stephan Drokin, Olivia Burke, Huayu Huang, Amy Leung, Marco Bravo-Manriquez, Myungkyu Jang, Marina S. Syrkina, Laura Julian, Nelson Sanjuan, Eric Tran

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...